In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 3, 2006, Pages 615-621

  Lotter, Kristina ^a   Höcherl, Klaus ^a   Bucher, Michael ^a   Kees, Frieder ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Interferon gamma; Interleukin 1 beta; Lipopolysaccharide; Nitric oxide; Telithromycin; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; KETOLIDE; MACROLIDE; MESSENGER RNA; NITRIC OXIDE; ROXITHROMYCIN; TELITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLORIMETRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; INFLAMMATORY DISEASE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; KETOLIDES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED STRAINS; NITRIC OXIDE; ORGAN SPECIFICITY; ROXITHROMYCIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS;

EID: 33747883370     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl270     Document Type: Article

References (37)

1. Bryskier A. Roxithromycin: Review of its antimicrobial activity. J Antimicrob Chemother 1998; 41 Suppl B: 1-21.
2. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41 Suppl B: 47-50.
3. Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-63.
4. Agen C, Danesi R, Blandizzi C et al. Macrolide antibiotics as antiinflammatory agents: Roxithromycin in an unexpected role. Agents Actions 1993; 38: 85-90.
5. Labro MT. Anti-inflammatory activity of macrolides: A new therapeutic potential? J Antimicrob Chemother 1998; 41 Suppl B: 37-46.
6. Culic O, Erakovic V, Pamham Md. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209-29.
7. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125: 41-50S.
8. Khan AA, Slifer TR, Araujo FG et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11: 121-32.
9. Suzaki H, Asano K, Ohki S et al. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm 1999; 8: 199-204.
10. Amsden GW. Anti-inflammatory effects of macrolides - an under-appreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
11. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52-60S.
12. Kudoh S, Azuma A, Yamamoto M et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-32.
13. Keicho N, Kudoh S. Diffuse panbronchiolitis: Role of macrolides in therapy. Am J Respir Med 2002; 1: 119-31.
14. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000; 6: 661-9.
15. Kuehnel TS, Schurr C, Lotter K et al. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chemother 2005; 55: 591-4.
16. Araujo FG, Slifer TL, Remington JS. Inhibition of secretion of interleukin-1alpha and tumor necrosis factor alpha by the ketolide antibiotic telithromycin. Antimicrob Agents Chemother 2002; 46: 3327-30.
17. Nakagawa S, Kojio S, Taneike I et al. Inhibitory action of telithromycin against Shiga toxin and endotoxin. Biochem Biophys Res Commun 2003; 310: 1194-9.
18. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-8.
19. Pfeilschifter J, Rob P, Mulsch A et al. Interleukin 1 beta and tumour necrosis factor alpha induce a macrophage-type of nitric oxide synthase in rat renal mesangial cells. Eur J Biochem 1992; 203: 251-5.
20. Cunha FQ, Assreuy J, Moss DW et al. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: Role of TNF-alpha and IL-1-beta. Immunology 1994; 81: 211-15.
21. Salvemini D, Marino MH. Inducible nitric oxide synthase and inflammation. Expert Opin Investig Drugs 1998; 7: 65-75.
22. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
23. Kooy NW, Royall JA, Ye YZ et al. Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med 1995; 151: 1250-4.
24. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-902.
25. Gaston B, Drazen JM, Loscalzo J et al. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994; 149: 538-51.
26. Kohri K, Tamaoki J, Kondo M et al. Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur Respir J 2000; 15: 62-7.
27. Terao H, Asano K, Kanai K et al. Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators Inflamm 2003; 12: 195-202.
28. Zacharowski K, Frank S, Otto M et al. Lipoteichoic acid induces delayed protection in the rat heart: A comparison with endotoxin. Arterioscler Thromb Vasc Biol 2000; 20: 1521-8.
29. Sass G, Heinlein S, Agli A et al. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 2002; 19: 115-20.
30. Baumgarten G, Knuefermann P, Nozaki N et al. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: The role of toll-like receptor-4. J Infect Dis 2001; 183: 1617-24.
31. Hocherl K, Dreher F, Kurtz A et al. Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 2002; 40: 947-53.
32. Shimizu S, Yamada Y, Okuno M et al. Liver injury induced by lipopolysaccharide is mediated by TNFR-1 but not by TNFR-2 or Fas in mice. Hepatol Res 2005; 31: 136-42.
33. Salkowski CA, Detore G, McNally R et al. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: The roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J Immunol 1997; 158: 905-12.
34. Kanai K, Asano K, Hisamitsu T et al. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J 2004; 23: 671-8.
35. Desaki M, Takizawa H, Ohtoshi T et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267: 124-8.
36. Kikuchi T, Hagiwara K, Honda Y et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002; 49: 745-55.
37. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94.